Materials development company Ceram Research Ltd (Stoke-on-Trent, UK) has signed an agreement with global pharma giant AstraZeneca (London) to develop its Inorganic-based Controlled Release Technology in a feasibility study for the delivery of select AstraZeneca compounds. If successful, the “technology could provide AstraZeneca with an alternative formulation approach for delivering these compounds,” said Ceram CEO, Tony Kinsella, in a press release issued by the company today.
Controlled Release Technology is one of several material development projects in the Ceram pipeline, including a multi-element substituted hydroxyapatite for orthopaedic device coating applications. Healthcare is one of Ceram’s largest markets, and the materials development business has ambitious plans to continue its growth in the United States and Europe. And that’s good news for the United Kingdom, adds Kinsella.
“Our work is focussed on commercial development of materials for industrial applications—exactly what a recent news item on the BBC said was lacking in Britain,” says Kinsella. “We have, for example, recently helped Greatbatch Medical to gain US FDA (510K) approval of a coating implant submission. We have also worked with GlaxoSmithKline in the proving of its Sensodyne toothpaste – a product that has seen substantial annual growth over the last decade, creating significant incomes for both GSK and the UK,” stresses Kinsella.Norbert Sparrow